Highest-materiality recent filing
Bio Green Med Solution Q1 2026 net loss $0.2M, fire safety revenue $0.8M
Net loss of $0.2M vs $0.1M in Q1 2025; prior year had $4.1M net income from discontinued ops.
Bio Green Med Solution declares $0.15 quarterly dividend on 6% Preferred Stock
Quarterly cash dividend of $0.15 per share declared on 6% Convertible Exchangeable Preferred Stock.
Bio Green Med Solution narrows 2025 net loss to $3.0M; records $0.7M fire safety revenue
Net loss for 2025 was $3.0M vs $11.2M in 2024; Q4 net loss of $0.6M vs $3.0M.
Bio Green Med preferred stock (BGMSP) to be delisted from Nasdaq for MVPHS non-compliance
Nasdaq notified BGMSP fails to maintain $1M minimum market value of publicly held shares; will delist.
Bio Green Med declares $0.15/share quarterly dividend on Preferred Stock
Board declared $0.15 per share cash dividend on 6% Convertible Exchangeable Preferred Stock (BGMSP).
Net loss of $1.0M for Q3 2025, halved from $2.0M in Q3 2024; cash $3.8M at Sept 30, 2025.
Bio Green Med exchanges 1.4M warrants for common stock under Section 3(a)(9) exemption
Aggregate of 1,402,605 shares of common stock issued in exchange for Series A, B, and C warrants originally issued in June 2025.
Sold all patent rights and IP related to Plogosertib (PLK1 inhibitor) to Tethra Biosciences Inc.
Bio Green Med declares $0.15 quarterly dividend on preferred stock
Quarterly cash dividend of $0.15 per share on 6% Convertible Exchangeable Preferred Stock.
Bio Green Med appoints Zara Pappas to board after Kwang Fock Chong resigns
Kwang Fock Chong resigned as independent director on Sept 19, 2025; no disagreement with the company.
Bio Green Med Solution files 8-K/A to correct logo on cover page; no substantive changes
Amendment filed solely to replace incorrect logo on cover page of Sept 12, 2025 Original 8-K.
Bio Green Med receives Nasdaq deficiency notice for preferred stock (BGMSP) over minimum MVPHS
Nasdaq notified that BGMSP's Market Value of Publicly Held Shares fell below $1M for 30 consecutive business days.
Bio Green Med (f/k/a Cyclacel) closes acquisition of Fitters Sdn. Bhd. for 699,158 shares
Issued 699,158 common shares (19.99% ownership) to FITTERS Diversified Berhad for 100% of Fitters Sdn. Bhd.
Shareholders approve stock issuance to Fitters Parent and name change to Bio Green Med Solution
Proposal to approve stock issuance to Fitters Parent passed with 58.8% of votes for (1,095,988 shares).
Cyclacel exchanges 559,395 Series C warrants for common stock
Exchanged 559,395 Series C warrants for 559,395 shares of common stock under Section 3(a)(9) exemption.
Amended warrants remove 4.99% Ownership Limitation on exercise and voting, effective September 1, 2025.
Cyclacel dismisses auditor Bush & Associates; going concern doubt flagged
Audit Committee dismissed Bush & Associates CPA LLP as independent auditor effective August 22, 2025.
Cyclacel faces going concern warning; cash of $3.45M expected only into Q2 2025
Auditor expresses substantial doubt about Cyclacel's ability to continue as a going concern; cash of $3.45M at March 31, 2025, expected to fund only into Q2 2025.
Cyclacel Q2 net loss $1.3M; cash $4.3M; share exchange with FITTERS on track
Net loss of $1.3M (incl. $7K stock comp) vs $3.3M in Q2 2024; revenue not reported.
Cyclacel removes ownership limitation on Series F Convertible Preferred Stock
Filed Amended Certificate of Designation removing Series F Ownership Limitation that capped conversion/voting at 4.99% of common stock.
Cyclacel Pharmaceuticals comments on recent stock price volatility, unaware of material changes
On July 15, 2025, Cyclacel's stock experienced significant volume and price movements.
Cyclacel amends exchange deal with FITTERS: adds $1M cash, extends closing to Sept 30
Amendment adds $1M cash consideration (or mutually agreed amount) to the existing stock-based consideration for FITTERS.
Cyclacel implements 1-for-15 reverse stock split effective July 7, 2025
Reverse split at 1:15 ratio, effective July 7, 2025; trading begins split-adjusted that day.
Cyclacel shareholders reelect directors, approve equity plan increase, endorse executive pay
Re-elected all five director nominees with over 99.97% support each.
Cyclacel raises $3M via convertible preferred stock and warrants; cash runway into Q3 2025
Gross proceeds of $3.0M from sale of 3M shares of Series F Convertible Preferred at $1.00 per share.
Cyclacel regains Nasdaq minimum bid price compliance
Received Nasdaq Compliance Notice dated June 3, 2025 confirming compliance with Listing Rule 5550(a)(2).
Cyclacel declares $0.15/share quarterly dividend on 6% Convertible Exchangeable Preferred Stock
Dividend of $0.15 per share on Preferred Stock (CYCCP) declared on June 3, 2025.
Cyclacel Pharmaceuticals Q1 2025: Deconsolidation Gain, FITTERS Exchange, Focus on Plogosertib
Cyclacel reported Q1 2025 net loss of $0.1 million, compared to $2.9 million in Q1 2024.
Reverse split ratio of 1-for-16; effective May 12, 2025 at market open.
Cyclacel enters share exchange to acquire Fitters Sdn. Bhd.; existing holders to own 80%
Cyclacel to exchange 19.99% of its common stock for 100% of Fitters Sdn. Bhd.
Cyclacel increases authorized common shares from 250M to 600M; removes Series E conversion cap
Board and majority stockholder approved Certificate of Amendment filed April 25, 2025.
Cyclacel declares $0.15 quarterly dividend on 6% Convertible Exchangeable Preferred Stock
Cash dividend of $0.15 per share on CYCCP (6% Convertible Exchangeable Preferred Stock).
Cyclacel reports Q4 net loss $3.0M; pro forma cash $7.2M; deconsolidates unit; board appointments
Net loss of $3.0M for Q4 2024 and $11.2M for full year; cash of $3.1M at Dec 31, 2024.
Cyclacel raises $1M via Series E convertible preferred stock; extends cash runway to Q3 2025
Gross proceeds of $1.0M from sale of 1M shares of Series E Convertible Preferred Stock at $1.00 per share.
Cyclacel acquires Plogosertib assets from liquidated subsidiary for £250K
Cyclacel Pharmaceuticals buys PLK1 inhibitor Plogosertib assets from wholly-owned UK subsidiary in liquidation for £250,000.
Cyclacel changes control; new majority owner holds 70% and appoints new CEO and CFO
Datuk Dr. Doris Wong Sing Ee bought 1M Series C and 1.745M Series D shares from ex-interim CEO David Lazar for $6.3M, gaining 70% ownership.
Purchase price amended to greater of closing bid at signing or prior to each purchase date.
Cyclacel removes preferred stock ownership caps and increases authorized shares to 250M
Stockholders removed Series C and D convertible preferred stock ownership limitations, eliminating conversion caps.
Lazar purchase agreement: up to $8M in Common Stock, exercisable by company until Sept 30, 2026, in $1M/$2M increments.
Cyclacel places UK subsidiary into CVL; to buy plogosertib, sell fadraciclib
UK subsidiary Cyclacel Ltd entered creditors voluntary liquidation; joint liquidators appointed.
Cyclacel corrects board appointment error in Securities Purchase Agreement with David Lazar
Addendum corrects inadvertent error: Mr. Lazar was not appointed as Board member or Chairman, only has right to appoint one director.
David E. Lazar invests $3.1M for 1M Series C (convertible at 2.65:1) and 2.1M Series D (110:1) preferred shares.
Cyclacel receives Nasdaq bid-price deficiency notice; stock at risk of delisting
Nasdaq notified Cyclacel on Dec 6, 2024, that common stock bid price below $1.00 for 30 consecutive business days.
Cyclacel raises $2.1M via warrant exercise, issues new warrants for ~19.9M shares
Gross proceeds ~$2.1M from cash exercise of 4,968,945 Series B warrants at reduced price $0.415/share.
Cyclacel dismisses auditor Crowe over warrant equity classification issue; engages Bush & Associates
Audit Committee dismissed Crowe LLP as auditor Nov 5, 2024; Crowe was engaged Aug 19, 2024.
Cyclacel Q3 net loss $2.0M, cash $3.0M; Nasdaq extension to Dec 24; going concern doubt
Net loss $2.0M for Q3 2024 vs $6.0M a year ago; cash $3.0M as of Sept 30, 2024.
Cyclacel gets Nasdaq extension to Dec 24, 2024 to meet equity minimum
Nasdaq Hearing Panel granted until Dec 24, 2024 to regain compliance with Rule 5550(b)(1).
Cyclacel suspends quarterly cash dividend on 6% Convertible Preferred Stock
Board resolved on Sept 4, 2024 to suspend Nov 1, 2024 quarterly dividend on Preferred Stock (CYCCP).
Cyclacel receives Nasdaq delisting notice for equity deficiency; hearing set for Oct 15, 2024
Nasdaq Staff determined Cyclacel's stockholders' equity was below $2.5M as of June 30, 2024, violating Listing Rule 5550(b)(1).
Stockholders' equity was $999K as of June 30, 2024, below Nasdaq's $2.5M minimum for continued listing.
on March 31, 2025, each of Avraham Ben-Tzvi and David Natan agreed to delay their previously announced resignation of their services to the Company as independent director from March 31, 2025 until the filing date of the Form 10-K. On such filing date, each of their resignation shall be automatically effective.
On March 31, 2025, David Lazar, the Company’s co-principal financial officer and co-principal accounting officer agreed to delay his previously announced resignation from March 31, 2025 until the date that the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”), is filed with the Securities and Exchange Commission (“SEC”). On such date, Mr. Lazar’s resignation shall be automatically effective.
On April 2, 2025, coinciding with the effective time of the resignation of Messers. Ben-Tzvi and Natan, as independent directors, the Company appointed Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, as independent directors, on the Company’s board of directors (the “Board”) to fill the vacancies and to hold office until their successor shall have been duly elected and qualified or until her or his earlier death, resignation or removal.
on March 31, 2025, each of Avraham Ben-Tzvi and David Natan agreed to delay their previously announced resignation of their services to the Company as independent director from March 31, 2025 until the filing date of the Form 10-K. On such filing date, each of their resignation shall be automatically effective.
On April 2, 2025, coinciding with the effective time of the resignation of Messers. Ben-Tzvi and Natan, as independent directors, the Company appointed Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, as independent directors, on the Company’s board of directors (the “Board”) to fill the vacancies and to hold office until their successor shall have been duly elected and qualified or until her or his earlier death, resignation or removal.
David Lazar, the Company’s interim Chief Executive Officer, interim principal financial officer, interim principal accounting officer, and Secretary, provided notice of his resignation as Chief Executive Officer and Secretary of the Company effective February 26, 2025.
Datuk Dr. Doris Wong Sing Ee was also elected to the Board of the Company as of the effective date.
the Board appointed Datuk Dr. Doris Wong Sing Ee, as Chief Executive Officer and, in such role, she will serve as the Company’s principal executive officer.
the Board of Directors appointed Mr. Lazar as interim Chief Executive Officer of the Company, effective as of the signing of the Purchase Agreement.
Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.
The Board of Directors also appointed Messrs. David Natan and Avraham Ben-Tzvi as members of the Board of Directors, effective as of the signing of the Purchase Agreement and as of January 5, 2025, respectively.
Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.
Max materiality 0.95 · Median 0.65 · Most common event other_material